About
Why Cogience
Better insights. Better decisions.
Better outcomes.
Market access success depends on the quality of the evidence, the clarity of the strategy, and the rigour of execution. Cogience works with pharmaceutical, biotech, and medical technology companies to raise the standard at every step, from evidence generation to payer decision.
What makes Cogience different
Four things that define how we work.
Direct access to expertise
Every engagement is led and delivered by senior specialists. You work with the expert, not an account manager passing work down.
Speed without sacrifice
Boutique structure means faster decisions, shorter approval chains, and more responsive execution. When your timeline shifts, we shift with it.
Tailored, not templated
We adapt our approach to your asset, your markets, and your organisation - not the other way around.
Quality built into the system
Our delivery methodology is governed through Cogience.Assure, our quality management platform aligned to ISO 9001 and ISO 42001. Controlled procedures, recorded review and approval, and a full audit trail - including for every use of AI.
Quality, transparency & oversight
Every deliverable is built to be defended.
In healthcare and life sciences consulting, the quality bar is set by the most demanding audience a deliverable will face - a payer committee, an HTA body, or a board. We build to that standard from the start.
Quality assurance
Senior expert review applied at every stage - not just at final delivery. Where AI tools are used, every output is validated by a qualified expert before inclusion in any deliverable.
Transparency by design
Clients can see how the work is done, which tools we use, and where we have made assumptions. Methodology, data sources, and AI use are documented clearly.
Risk & issue management
Risks identified at kick-off and tracked throughout. Issues escalated immediately - never managed quietly. Clients see any scope, timeline, or quality risk at every review call.
Monitoring & reporting
Progress reported against the agreed plan at every weekly review. Interim reports summarise findings to date, flag open questions, and confirm next steps. Nothing is held back for the final.
How we deliver
The speed of AI. The rigour of senior experts.
AI tools can now accelerate literature review, evidence synthesis, economic modelling, and document production by 40–80% compared to traditional methods. We use them. But in healthcare and life sciences, speed without accuracy is a liability - HTA bodies, payers, and regulators expect evidence packages that are methodologically sound, fully traceable, and defensible under scrutiny. That standard cannot be met by AI alone.
AI-enabled
Tooling deployed where it delivers genuine efficiency.
- AI-assisted literature screening and data extraction
- Code scaffolding for economic models (R, Python)
- RWD-to-RWE computational pipelines
- LLM-assisted dossier and value-document drafting
- Automated reporting and project tracking
Expert-led
Senior oversight where judgement and accountability matter.
- Protocol design, GRADE, and HTA conclusions
- Model structure, assumptions, and HTA alignment
- Verification of all numerical outputs
- Clinical and commercial accuracy of value narrative
- Senior-led client relationship throughout
The Cogience Engagement Model
Shape. Build. Defend.
The same structure on every project, whatever the scope: three phases across six steps, so you always know where the work stands.
Scope, success criteria, and the question worth defending.
Evidence, models, and dossier components - built and pressure-tested in the open.
A submission package ready for HTA, payer, and committee scrutiny - and a team that can answer the questions.
-
01
Kick-off
Align on objectives, scope, timeline, and success criteria. Establish working rhythms and communication channels.
-
02
Weekly review calls
Standing touchpoint to review progress, share interim findings, and resolve blockers. No surprises between milestones.
-
03
Interim reports
Structured progress documents at defined milestones. Findings to date, open questions, next steps, emerging risks.
-
04
Interim presentation
Mid-project deep-dive for longer engagements. Pressure-test direction and adjust scope where needed.
-
05
Final presentation
Complete findings, recommendations, and next steps - delivered to the right audience at the right level of detail.
-
06
Post-delivery
Available for follow-on questions, implementation support, or extensions as the project evolves.
Dr. Farzana Malik
Managing Partner
Team
25 years of market access leadership.
Dr. Farzana Malik founded Cogience to offer the senior-led consulting that large firms usually reserve for their biggest clients.
Her background spans industry leadership roles at Pfizer, Alexion, Serono, and Medtronic, followed by more than a decade as an independent advisor with 50+ global engagements across market access, commercialisation, pricing, and due diligence.
- PhD in Health Economics & Health Care Management, University of St Andrews
- Steering Committee, Rare Disease Interest Group, HTA International
- Part-time Lecturer, Pricing & Reimbursement of Medical Devices, University of Bern (2021–2025)
- Board Advisor to several life-science start-ups
- Recognised international conference presenter, moderator, and published author
Senior advisors & network
Boutique by design, backed by a global expert network.
Cogience works with a curated network of senior advisors, payers and country experts across Europe, the Americas and Asia-Pacific. We bring them in where an engagement needs local payer insight, so clients get market-specific answers without the cost of a large consulting footprint.
What clients say
Voices from the engagements.
"As a full-time consultant working with my Market Access team, Farzana impressed me with both her industry knowledge and technical pricing expertise."
"…"
"…"
Boutique by design.
Not by default.
Cogience is deliberately boutique. Every engagement is led by a senior consultant with direct client responsibility - no juniors doing the work behind the scenes.
We do more with less. By embedding AI and modern technology into how we work, a lean team of senior advisors delivers what used to take a department, faster and more accurately.
Backed by a global payer advisory network, we provide local market intelligence and rapid research without the overhead of a traditional consulting footprint.
The case for boutique
Senior expertise, no delegation.
What we don't do
Boundaries we keep, deliberately.
A boutique that says yes to everything stops being a boutique. These are the engagements we turn down, so the work we take on stays senior-led and defensible.
-
We don't run clinical trials.
Trial operations belong with CROs and sponsors. We design the evidence package around the trial, not the other way around.
-
We don't sell software licences.
Our platforms, such as Cogience.Advise, are tools we use inside engagements. We don't package them as SaaS or charge per seat.
-
We don't subcontract to junior offshore teams.
Senior experts execute. AI accelerates. If a deliverable needs someone you'd put in front of a payer committee, it stays in-house.
-
We don't take work outside our specialism.
If an engagement sits outside market access, health economics, HTA, or the AI workflows around them, we'll tell you that on the first call.
Ready to scope an engagement?
Tell us about the asset, the question, and the markets in scope. We'll reply within one working day.
Book a 30-minute call